IVVD: Phase III data for a scalable COVID-19 monoclonal antibody is imminent, with broad market ambitions
The company is advancing a next-generation monoclonal antibody for COVID-19, with phase III data imminent and regulatory strategies under consideration. Plans include transitioning to a more scalable, vaccine-like product and expanding into other infectious diseases, targeting both immunocompromise…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.